Researchers have developed a human stem-cell model that recreates early immune-cell development and shows how a single progenitor population can give rise to specialized macrophages across different organs. The model provides a platform to study how these processes change in disease, and how they might eventually be harnessed therapeut...
Researchers developed a nano-activator that drives localized immune activation to eliminate tumors without complex antigen screening. The platform successfully remodeled the immunosuppressive tumor microenvironment and induced a durable, systemic immune memory.
Researchers discovered inducible germinal center-like structures in common carp gut, showing conserved molecular programs and cell-cell communication networks. These findings suggest that sophisticated mucosal adaptive immunity emerged early in vertebrate evolution.
A study in mice shows that K3-SPG, a vaccine adjuvant, can activate innate immunity, providing a potential temporary defense against respiratory viruses. The treatment also protected mice against SARS-CoV-2, but its effects were mainly limited to tolerating the infection and limiting tissue damage.
Research identifies N6-methyladenosine as a critical regulator in IBD pathogenesis, influencing intestinal barriers and immune responses. The study highlights the potential of targeting the m6A pathway for precision diagnosis, individualized therapy, and prognosis prediction.
Cysteine peptidases govern antigen-presenting cell function and antitumor immunity, with excessive activity leading to tumor immune evasion. Therapeutic targeting of cysteine peptidases holds promise for cancer immunotherapy, with combination therapies showing synergistic antitumor effects.
A new study found that the gut microbiome, influenced by diet, plays a key role in shaping vaccine side effects, including fever and inflammation. The study suggests that targeting the microbiome could reduce vaccine-related inflammation without compromising immune protection.
Researchers identified a combination treatment that reprograms myeloid cells and boosts T cells, shrinking tumors and preventing recurrence. The approach showed a 40% long-term survival rate in murine models and holds promise for other types of recalcitrant cancer.
Dr. Derek Janssens' lab will develop and apply new techniques for studying epigenetics, a relationship with vast implications for health. They will analyze blood samples from people with myelodysplastic syndrome and lupus to understand epigenetic changes that drive disease-related changes in the body.
Chemotherapies like CarboTaxol enhance cancer vaccine responses by expanding a pool of T cells that express the factor TCF1, rejuvenating their life and functionality. This effect is further enhanced when combined with immunotherapy, showing potential for improved clinical trial outcomes.
The Terasaki Institute has been awarded $19.8 million to engineer transplantable, immune-compatible liver tissue, addressing a shortage of donor organs. The project, called Prometheus, aims to ease donor scarcity and the lifelong immunosuppression required by transplant patients.
Scientists at Duke-NUS Medical School analyzed 3.8 million immune cells from nearly 2,000 people to uncover how healthy immune cells change differently in men and women as they age. The study found distinct waves of immune ageing and sex-specific changes, shedding light on why some autoimmune conditions disproportionately affect women.
Researchers found that host immune status significantly influences herpesvirus retinitis phenotypes and clinical outcomes. Acute retinal necrosis (ARN) is associated with a higher risk of retinal detachment, while cytomegalovirus retinitis (CMVR) follows an indolent course.
New research reveals that bacteria detect viruses when a viral enzyme cuts an important sensor molecule, triggering an immune response. This discovery could lead to the development of more effective phage therapies that can evade bacterial immune systems.
Researchers have discovered that γδ T cells use adaptive immune receptors to drive rapid, innate-like responses to tissue stress, inflammation, and cancer. These cells rely on the receptor to maintain and mount rapid tissue surveillance responses, making them a promising candidate for next-generation cancer immunotherapies.
Allergen immunotherapy (AIT) is showing promising results in reducing clinical symptoms and severity of allergic diseases, including asthma and allergic rhinitis. The latest advances in AIT include innovative technologies and biomarkers that predict and monitor treatment response.
Researchers found that microplastics clog liver phagocytes, disrupting metabolism and leading to fatty liver disease. In contrast, smaller particles activated brown adipose tissue, stimulating heat production.
A University of Maryland study predicts that repealing Florida's measles vaccine mandate could spark the largest measles epidemic in the US in nearly 500 years. The study shows that even without mandate removal, Florida's vaccine-induced herd immunity threshold is below the level needed to protect against sustained transmission.
Group 2 innate lymphoid cells (ILC2s) form tight anatomical associations with sensory, autonomic, and enteric nerve fibers, receiving neural regulation through activating and inhibitory pathways. ILC2s also secrete cytokines that can act back on neurons, forming positive feedback loops that modulate allergic and anti-infective immunity.
A novel autologous gene therapy for Wiskott-Aldrich syndrome has demonstrated durable clinical benefits in a phase 3 study, with 96% survival at 1 and 5 years. The treatment, etu-cel, has also reduced severe infections and moderate-to-severe bleeding events.
Researchers found that a natural enzyme derived from figleaf gourd can significantly reduce the immunoreactivity of peanut proteins, pointing to a potential new approach to developing food ingredients with reduced allergenic potential. Enzymatic hydrolysis can alter protein properties, reducing antibody recognition, but not eliminating...
Researchers discovered a link between the nervous system and the development of neuroendocrine prostate cancer, a form of prostate cancer that is aggressive and resistant to treatment. The study found that high levels of a neurotransmitter called neuromedin U support tumor progression by blocking the immune response.
Researchers found that AS01 adjuvant induces trained immunity in human monocytes and reduces tumor growth in selected mouse cancer models. The treatment also alters the tumor microenvironment, increasing frequencies of immune cells and reducing tumor-associated macrophages.
Researchers found similar diarrhea outcomes among patients with low and normal fecal elastase levels, suggesting stool dilution is a possible cause. Fecal fat testing is recommended before enzyme therapy to confirm exocrine pancreatic insufficiency.
Researchers identified a previously unknown pathway that prostate tumors leverage to suppress the immune system, reshaping the tumor microenvironment to resist treatment. Combining B7-H3-targeted therapy with MEK inhibition improved antitumor responses and prolonged survival in preclinical models of castration-resistant prostate cancer.
Researchers found that sensory neurons retain a memory of allergens that may explain why allergies develop over time. This memory primes neurons to respond more strongly to later exposures, even after the original allergen is gone.
The Terasaki Institute faculty has developed a next-generation immunomodulatory wound dressing platform designed to accelerate healing in chronic wounds. The platform is designed to deliver oxygen directly to the wound and use a specialized peptide to encourage immune cells to support healing.
The new guidelines, developed by leading experts, focus on improving sepsis care by strengthening systems for diagnosis, treatment, prevention, and quality improvement. Emerging technologies, such as next-generation diagnostics and artificial intelligence, are also being explored to enhance sepsis care.
Researchers discovered that gut bacteria produce vaccenic acid, a substance that activates the LRH-1 receptor, improving metabolic health and reducing inflammation. The study highlights the crucial role of the gut microbiome in regulating physiological processes and overall metabolism.
The cGAS-STING pathway connects cellular aging to brain inflammation, with self-DNA accumulating in the cytoplasm and triggering chronic inflammation. Mitochondrial DNA plays a key role in this process, linking metabolic dysfunction to glial activation and neuronal damage.
Christopher Goodnow's work challenged the concept of complete clonal deletion, revealing self-reactive B cells' ability to acquire self-tolerance and potentially cause autoimmune disease. His research discovered that these cells are essential for immune function and can be converted into functional B cells through 'clonal redemption'.
UCLA researchers are launching a phase 1/2 clinical trial to evaluate the safety and efficacy of JAK inhibitors in preventing immune checkpoint inhibitor-induced type 1 diabetes. The trial aims to test whether these drugs can protect insulin-producing cells in patients who develop diabetes after cancer immunotherapy.
Researchers develop a new approach combining probiotics with T cells to improve tumor localization and coordination of local immune responses. The therapy, called T-FOLactis, shows improved tumor control and median survival in mouse colorectal cancer models.
XKH004 effectively improves ankylosing spondylitis symptoms and physical functions over 52 weeks, with significant increases in clinical remission and reductions in systemic inflammation and pain. Long-term safety performance is stable and controllable, making it a promising treatment option for refractory patients.
Salk Institute researchers have discovered a novel pathway that links chronic interferon II exposure to mitochondrial dysfunction, leading to immunosuppression and enhanced tumor growth. By blocking prostaglandin E2, they found a viable target to restore immune system function and combat immunotherapy resistance.
The 2026 Josep Carreras Institute Symposium explores the latest immunology advances in haematological malignancies, transforming treatment landscapes with CAR-T therapies and checkpoints. Major challenges remain in understanding tumour-immune system interactions and therapeutic resistance.
A team of researchers from the University of Osaka found that cells producing IgG1 antibodies have advantages over those producing IgM antibodies, including better antigen presentation, survival, and bone marrow migration. These advantages may lead to long-term immune protection and inform the development of more effective vaccines.
A new strategy has been developed to help macrophages stay active inside tumors. Tiny patches are attached to macrophages, which break down and release zinc ions to activate the immune system. This approach combines immune-cell reprogramming with tumor-environment remodeling, helping macrophages regain anti-tumor activity.
A modular nano-adaptor approach tunes T-cell activation to control CD3 activation and prevent toxicity, increasing therapeutic effectiveness in solid tumors. The platform has identified promising lead designs for multispecific nanoantibody configurations.
mRNA-LNPs are shifting the paradigm of drug delivery, enabling vaccines, personalized cancer vaccines, and in vivo gene editing. CAR-engineered cells can be directly generated in vivo, offering a streamlined alternative to ex vivo CAR-T manufacturing.
Cancer cells release natural antioxidants, such as Peroxiredoxin 1, to suppress immune-cell activity and prevent destruction. Removing this antioxidant production enhances the cancer's response to immunotherapy.
Salk Institute scientists found that maternal immune activation leads to epigenetic changes in mouse brains, increasing the risk of neurodevelopmental disorders. These changes were particularly significant in areas of the genome associated with autism spectrum disorder.
Research reveals UBE2M's critical regulatory link to inflammation and innate immune pathway in KrasG12D driven non-small cell lung cancer. Simultaneous UBE2M deletion and KrasG12D activation causes severe inflammatory TME, shortening life-span and promoting tumor growth.
Researchers have created a detailed map of childhood Crohn's disease before and after treatment, identifying specific cell signatures that predict disease severity and treatment outcomes. The study suggests that anti-TNF therapy may push the pediatric cell ecosystem towards more resistant disease.
Children's Hospital Colorado has launched a Sublingual Immunotherapy Program to treat children with 10 common food allergies, including milk, egg, peanut, and sesame. The program involves daily liquid drops under the tongue and may gradually build tolerance and provide greater protection against accidental exposure.
Immunotherapy for gynecological tumors offers durable responses and survival benefits, but complex immune evasion mechanisms and tumor microenvironment pose challenges. Current treatment options, such as ICIs and adoptive cell therapy, show promise, but precision immunotherapy is needed to improve patient outcomes.
Tumor-infiltrating lymphocyte therapy has shown potential in several types of solid tumors, including metastatic melanoma, breast cancer, and ovarian cancer. Despite challenges, the approach has favorable clinical outcomes, and researchers are exploring combination strategies and advanced technologies to improve treatment durability.
Researchers have identified a subset of B cells known as atypical memory cells as the primary precursors of autoantibody-producing cells during SARS-CoV-2 infection. These cells adopt a markedly different biological program, leading to increased autoantibody production. The study provides new insight into how viral infections can trigg...
Researchers discovered how tumors interact with the body to grow and spread, revealing a new target for cancer therapy. Metadherin, a protein encoded by the MTDH gene, mediates this metabolic-immune crosstalk, supporting tumor growth and metastasis.
Researchers have created a high-resolution functional map of human immune cells, revealing intricate circuits that govern health and disease. The dataset provides a powerful framework for designing cancer immunotherapies and treating autoimmune conditions, and serves as a foundation for AI models of biology.
Researchers have identified a hidden defect in the gut that can damage intestinal cells, even in patients with well-controlled disease. The study found that this defect can be present in patients with clinically mild disease and can lead to future flares.
A review by Professor Di Wang and Dr. Zheyu Chi proposes a conceptual framework in which immunometabolism is shaped by the local repair niche, influencing tissue repair trajectories. Organ-specific metabolic microenvironments uniquely shape immune cell function, necessitating targeted therapeutic interventions.
Researchers found that dietary tryptophan supplementation can prevent sepsis by enhancing macrophage bacterial defense through GPR37 activation, which increases phagocytic ability against bacteria. IPyA, a key metabolic product, directly binds to GPR37 on macrophages, activating RAC1/CDC42 and increasing phagocytosis.
Researchers found that alveolar type 2 cells mount slower interferon-driven antiviral defenses than type 1 cells, enabling higher viral replication in the alveoli. This study provides new insights into the primary site of influenza virus damage and opens up potential targets for antiviral therapy.
Scientists have identified multiple targets for antibodies that could treat Crimean-Congo hemorrhagic fever, a deadly virus spread by ticks. The research found that antibodies targeting the nucleocapsid protein offer protection against the virus, regardless of strain, and could lead to the development of new treatments.
Researchers discovered that Trypanosoma cruzi, the Chagas disease parasite, alters its RNA to adapt to infect mammals, a process that could lead to new treatments. The study found that modifications in transfer RNA facilitate protein production, influencing the parasite's transformation from a non-infective to an infectious phase.
Researchers review glioma microenvironment and related therapeutic strategies, highlighting the need to disrupt neuron-tumor communication and reprogram the immune landscape. This review provides a conceptual framework for next-generation therapies and marks a fundamental shift in glioma therapeutics.
Scripps Research scientist Tiantian Liu has received a $2.76 million NIAID New Innovators Award to study immune cell biology and develop new therapies that harness T cell responses. Her research aims to advance fundamental knowledge of how immune cells activate T cells to combat infectious diseases.
A study led by German Cancer Research Center researchers found that the WNT signaling pathway helps cancer cells suppress the immune system, promoting the development of malignant tumors. Restoration of CCL20 production slowed tumor growth in experimental models.
Researchers at MIT developed a new cell-preservation technique using naturally occurring sugars, reducing the need for a chemical preservative. This approach significantly improves the viability and function of CAR-T cells, making them easier to deploy in hospitals.